Telix Pharmaceuticals

Telix Pharmaceuticals develops theranostic radiopharmaceuticals for cancer and rare diseases, pairing diagnostic imaging with targeted radiation to support personalised treatment. A commercial-stage biopharmaceutical company, it pursues a broad pipeline across urologic oncology, neuro-oncology and musculoskeletal cancers, underpinned by a global supply, manufacturing and distribution network. Its regulatory approval for Illuccix imaging supports markets worldwide, with a portfolio focused on precision radiopharmaceuticals.

Telix Pharmaceuticals is public listed, with a valuation of -.

Alternatives.pe lists Telix Pharmaceuticals's financials, valuation trends, ownership structure and transaction activity.

You're on a preview of a profileGet a free trial to view it in full

Last Updated: 2026-07-21

You're on a preview of a profileGet a free trial to view it in full

Last Updated: 2026-07-21

Loading, please wait...

All information here may not be reproduced without explicit written permission from Alternatives.pe.

Glossary

Telix Pharmaceuticals

Telix Pharmaceuticals

Key Team Members

Documents

Related News

Employee Count

Key Team Members